Sepranolone normalizes the spontaneous GABA-A receptor activity induced by Allopregnanolone. It does this by inhibiting the Positive Allosteric Modulation (PAM) effect of ALLO within the GABA-A receptor.
The finely targeted specificity of Sepranolone means that it is confined to a very specific part of the GABA-A receptor, with minimal effect on any other CNS mechanism—meaning little or no side effects as a treatment:
Fine-tuned receptor activity without overstimulation